Ginkgo Bioworks Holdings (Ginkgo Bioworks Holdings) Cash-to-Debt : 3.91 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Ginkgo Bioworks Holdings Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Ginkgo Bioworks Holdings's cash to debt ratio for the quarter that ended in Dec. 2023 was 3.91.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Ginkgo Bioworks Holdings could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Ginkgo Bioworks Holdings's Cash-to-Debt or its related term are showing as below:

DNA' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.97 Med: 13.15 Max: 67.3
Current: 3.91

During the past 5 years, Ginkgo Bioworks Holdings's highest Cash to Debt Ratio was 67.30. The lowest was 2.97. And the median was 13.15.

DNA's Cash-to-Debt is ranked worse than
58.41% of 1539 companies
in the Biotechnology industry
Industry Median: 6.5 vs DNA: 3.91

Ginkgo Bioworks Holdings Cash-to-Debt Historical Data

The historical data trend for Ginkgo Bioworks Holdings's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Ginkgo Bioworks Holdings Cash-to-Debt Chart

Ginkgo Bioworks Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

N/A

22.40

67.30

2.97

3.91

Ginkgo Bioworks Holdings Quarterly Data
	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial										2.97	2.99	2.69	2.60	3.91

Competitive Comparison of Ginkgo Bioworks Holdings's Cash-to-Debt

For the Biotechnology subindustry, Ginkgo Bioworks Holdings's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ginkgo Bioworks Holdings's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ginkgo Bioworks Holdings's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Ginkgo Bioworks Holdings's Cash-to-Debt falls into.

Ginkgo Bioworks Holdings Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Ginkgo Bioworks Holdings's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	944.073	/	(19.933	+	221.835)
	=	3.90

Ginkgo Bioworks Holdings's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	944.073	/	(19.933	+	221.835)
	=	3.90

Ginkgo Bioworks Holdings (NYSE:DNA) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Ginkgo Bioworks Holdings Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Ginkgo Bioworks Holdings's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Ginkgo Bioworks Holdings (Ginkgo Bioworks Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ginkgo Bioworks Holdings Inc (NYSE:DNA) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

DNA.WS:USA DNA:Mexico

Address

27 Drydock Avenue, 8th Floor, Boston, MA, USA, 02210

Website

https://www.ginkgobioworks.com

Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Foundry and Biosecurity. The Biosecurity segment generates the majority of revenue.

Executives

Jason R Kelly	director, officer: CEO & Founder	667 MADISON AVENUE, C/O CORVEX MANAGEMENT LP, NEW YORK NY 10065
Mark E. Dmytruk	officer: Chief Financial Officer	C/O SOARING EAGLE ACQUISITION CORP., 955 FIFTH AVENUE, NEW YORK NY 10075
Barry Canton	10 percent owner	C/O GINKGO BIOWORKS, INC., 27 DRYDOCK AVENUE, 8TH FLOOR, BOSTON MA 02210
Reshma P. Shetty	director, 10 percent owner, officer: President, COO & Founder	C/O SOARING EAGLE ACQUISITION CORP., 955 FIFTH AVENUE, NEW YORK NY 10075
Christian O Henry	director	9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Harry Sloan	director, officer: CEO, Chairman	1450 2ND STREET, SUITE 247, SANTA MONICA CA 90401
Shyam Sankar	director	C/O PALANTIR TECHNOLOGIES INC., 1200 17TH STREET, FLOOR 15, DENVER CO 80202
Steven P. Coen	officer: Chief Accounting Officer	C/O GINKGO BIOWORKS HOLDINGS, INC., 27 DRYDOCK AVENUE, 8TH FLOOR, BOSTON MA 02210
Marie E. Fallon	officer: Chief Accounting Officer	C/O GINKGO BIOWORKS, INC., 27 DRYDOCK AVENUE, 8TH FLOOR, BOSTON MA 02210
Marijn E Dekkers	director	GENERAL ELECTRIC COMPANY, 41 FARNSWORTH STREET, BOSTON MA 02210
Kathy Hopinkah Hannan	director	ANNALY CAPITAL MANAGEMENT, INC., 1211 AVE. OF THE AMERICAS, NEW YORK NY 10036
David C. Ott	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Parent Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Investors Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Gp Llc	10 percent owner	55 RAILROAD AVENUE, GREENWICH CT 06830